Use of the injectable contraceptive Depo-Provera is known to be associated with an increase in HIV transmission. In August this year, the World Health Organization came out with a new guidance for its use in populations with high prevalence of HIV. This editorial by C. Sathyamala commissioned by the British Medical Journal argues that the WHO’s new guidance fails to protect women and girls in high prevalence countries.
Use of the injectable contraceptive Depo-Provera is known to be associated with an increase in HIV transmission. In August this year, the World Health Organization came out with a new guidance for its use in populations with high prevalence of HIV.
This editorial by C. Sathyamala commissioned by the British Medical Journal, argues that the WHO’s new guidance fails to protect women and girls in high prevalence countries.
- Researcher
- More information
Read the article online - Depot contraception and HIV: an exercise in obfuscation
